0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?

      other

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The pace of scientific progress over the past several decades within the biological, drug development, and the digital realm has been remarkable. The’omics revolution has enabled a better understanding of the biological basis of disease, unlocking the possibility of new products such as gene and cell therapies which offer novel patient centric solutions. Innovative approaches to clinical trial designs promise greater efficiency, and in recent years, scientific collaborations, and consortia have been developing novel approaches to leverage new sources of evidence such as real-world data, patient experience data, and biomarker data. Alongside this there have been great strides in digital innovation. Cloud computing has become mainstream and the internet of things and blockchain technology have become a reality. These examples of transformation stand in sharp contrast to the current inefficient approach for regulatory submission, review, and approval of medicinal products. This process has not fundamentally changed since the beginning of medicine regulation in the late 1960s. Fortunately, progressive initiatives are emerging that will enrich and streamline regulatory decision making and deliver patient centric therapies, if they are successful in transforming the current transactional construct and harnessing scientific and technological advances. Such a radical transformation will not be simple for both regulatory authorities and company sponsors, nor will progress be linear. We examine the shortcomings of the current system with its entrenched and variable business processes, offer examples of progress as catalysts for change, and make the case for a new cloud based model. To optimize navigation toward this reality we identify implications and regulatory design questions which must be addressed. We conclude that a new model is possible and is slowly emerging through cumulative change initiatives that question, challenge, and redesign best practices, roles, and responsibilities, and that this must be combined with adaptation of behaviors and acquisition of new skills.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: not found
          • Article: not found

          On the Fintech Revolution: Interpreting the Forces of Innovation, Disruption, and Transformation in Financial Services

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Comparing technological hype cycles: Towards a theory

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Project Orbis: Global Collaborative Review Program

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Med (Lausanne)
                Front Med (Lausanne)
                Front. Med.
                Frontiers in Medicine
                Frontiers Media S.A.
                2296-858X
                21 May 2021
                2021
                : 8
                : 660808
                Affiliations
                [1] 1Global Regulatory Policy and Intelligence, Pfizer , Tadworth, United Kingdom
                [2] 2Global Regulatory Policy and Intelligence, Pfizer , Groton, CT, United States
                [3] 3Global Biometrics and Data Management, Pfizer , Sandwich, United Kingdom
                [4] 4Global Regulatory Operations, Pfizer , Sandwich, United Kingdom
                Author notes

                Edited by: Steffen Thirstrup, NDA Advisory Services Ltd., United Kingdom

                Reviewed by: Robert Meyer, University of Virginia, United States; Ana Paula Martins, University of Lisbon, Portugal; Thomas Lonngren, NDA Group, United Kingdom

                *Correspondence: Judith C. Macdonald judith.c.macdonald@ 123456pfizer.com

                This article was submitted to Regulatory Science, a section of the journal Frontiers in Medicine

                Article
                10.3389/fmed.2021.660808
                8183468
                34109196
                e81f7367-b89d-4f1a-8954-26c922a91623
                Copyright © 2021 Macdonald, Isom, Evans and Page.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 29 January 2021
                : 12 April 2021
                Page count
                Figures: 3, Tables: 1, Equations: 0, References: 36, Pages: 12, Words: 9094
                Categories
                Medicine
                Policy and Practice Reviews

                regulatory,digital,dynamic,cloud,review,artificial intelligence (ai),machine based learning,ecosystem

                Comments

                Comment on this article